Phillip Fleshner
Overview
Explore the profile of Phillip Fleshner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Akhlaghpour M, Haritunians T, More S, Thomas L, Stamps D, Dube S, et al.
Gut
. 2023 Apr;
72(11):2068-2080.
PMID: 37080587
Objective: Perianal Crohn's disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We...
12.
Aviran E, Assaf D, Zaghiyan K, Fleshner P
Dis Colon Rectum
. 2023 Mar;
66(5):700-706.
PMID: 36856670
Background: Crohn's disease is considered a contraindication for IPAA. In our prior study, when IPAA was used intentionally for well-defined Crohn's disease, we found a high incidence of recurrent disease...
13.
14.
Aviran E, Zaghiyan K, Fleshner P
Dis Colon Rectum
. 2022 Nov;
65(S1):S105-S112.
PMID: 36399770
Background: Total proctocolectomy with IPAA reconstruction is the surgical approach of choice in ulcerative colitis, indeterminate colitis, familial adenomatous polyposis, and selected patients with Crohn's disease. Pouch stricture is a...
15.
Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, et al.
Clin Gastroenterol Hepatol
. 2022 Nov;
21(9):2359-2369.e5.
PMID: 36343846
Background & Aims: We compared the safety and effectiveness of tumor necrosis factor α (TNF-α) antagonists vs vedolizumab vs ustekinumab in patients with Crohn's disease (CD) in a multicenter cohort...
16.
Cohen B, Fleshner P, Sands B
Gastroenterology
. 2022 Sep;
164(2):308-309.
PMID: 36155193
No abstract available.
17.
Celentano V, Adamina M, Spinelli A, Fleshner P, Pellino G, Mineccia M, et al.
Colorectal Dis
. 2022 Sep;
25(2):282-288.
PMID: 36109836
Background: There are reported variations in the intraoperative management of Crohn's disease. This consensus statement aimed to develop a standardised protocol for photographic documentation of intraoperative findings and critical procedural...
18.
Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk J, et al.
Am J Gastroenterol
. 2022 Aug;
117(10):1639-1647.
PMID: 35973139
Introduction: Obesity is variably associated with treatment response in biologic-treated patients with inflammatory bowel diseases (IBD). We evaluated the association between obesity and risk of hospitalization, surgery, or serious infections...
19.
Nguyen N, Luo J, Paul P, Kim J, Syal G, Ha C, et al.
Clin Gastroenterol Hepatol
. 2022 Jun;
21(1):173-181.e5.
PMID: 35644340
Background & Aims: There are limited data on outcomes of biologic therapy in Hispanic patients with inflammatory bowel diseases (IBDs). We compared risk of hospitalization, surgery, and serious infections in...
20.
Cohen B, Fleshner P, Kane S, Herfarth H, Palekar N, Farraye F, et al.
Gastroenterology
. 2022 Apr;
163(1):204-221.
PMID: 35413359
Background & Aims: Whether preoperative treatment of inflammatory bowel disease (IBD) with tumor necrosis factor inhibitors (TNFis) increases the risk of postoperative infectious complications remains controversial. The primary aim of...